{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:22:51Z","timestamp":1761060171640,"version":"3.44.0"},"reference-count":9,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2016,7,11]]},"abstract":"<jats:p>Hysteroscopic sterilisation with Essure requires confirmation of tubal occlusion by hysterosalpingogram or microinsert position by transvaginal sonography 3\u2005months after placement before women can rely on the method for pregnancy prevention. A 39-year-old woman underwent hysteroscopic sterilisation via Essure, with successful bilateral tubal occlusion documented on hysterosalpingogram. She had a subsequent unintended pregnancy and termination, and presented with persistent pelvic pain and other non-specific symptoms. She underwent a laparoscopic-assisted vaginal hysterectomy with bilateral salpingectomy, with complete resolution of her symptoms. Pathological evaluation demonstrated a perforated Essure microinsert and ipsilateral tubal occlusion, and a correctly placed Essure microinsert with ipsilateral tubal patency. Clinicians should be cautious about the assumption that correctly placed microinserts based on ultrasonography, hysterosalpingogram or laparoscopic evaluation assures occlusion success.<\/jats:p>","DOI":"10.1136\/bcr-2016-216535","type":"journal-article","created":{"date-parts":[[2016,7,27]],"date-time":"2016-07-27T11:33:52Z","timestamp":1469619232000},"page":"bcr2016216535","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Discordant relationship between Essure microinsert position and tubal occlusion"],"prefix":"10.1136","volume":"2016","author":[{"given":"Melody Y","family":"Hou","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of California, Davis School of Medicine, Sacramento, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2016,7,27]]},"reference":[{"key":"2025082623334265000_2016.jul27_1.bcr2016216535.1","unstructured":"Camlin C , Escandon I . Sterilization incidence and prevalence. In: Landry E, ed. Contraceptive sterilization: global issues and trends. New York, NY: EngenderHealth, 2002:16\u201364."},{"key":"2025082623334265000_2016.jul27_1.bcr2016216535.2","unstructured":"Ahlborg J , Cordero C , Cullins V , et al . Female sterilization. In: Landry E, ed. Contraceptive sterilization: global issues and trends. New York, NY: EngenderHealth, 2002:139\u201360."},{"key":"2025082623334265000_2016.jul27_1.bcr2016216535.3","unstructured":"Bayer HealthCare Pharmaceuticals. Essure permanent birth control: Instructions for use. Milpitas, CA: Bayer Healthcare LLC, 2002."},{"key":"2025082623334265000_2016.jul27_1.bcr2016216535.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1510514"},{"key":"2025082623334265000_2016.jul27_1.bcr2016216535.5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i1283"},{"key":"2025082623334265000_2016.jul27_1.bcr2016216535.6","unstructured":"Bayer HealthCare Pharmaceuticals. U.S. FDA Approves Alternate Confirmation Test for Essure Permanent Birth Control [press release]. July 1, 2015, PR Newswire, http:\/\/www.prnewswire.com\/news-releases\/us-fda-approves-alternate-confirmation-test-for-essure-permanent-birth-control-300107554.html"},{"key":"2025082623334265000_2016.jul27_1.bcr2016216535.7","unstructured":"U.S. Food and Drug Administration. Essure Permanent Birth Control: FDA's Review of Reported Problems. 2015 (updated 9\/16\/2015). http:\/\/www.fda.gov\/MedicalDevices\/ProductsandMedicalProcedures\/ImplantsandProsthetics\/EssurePermanentBirthControl\/ucm452254.htm"},{"key":"2025082623334265000_2016.jul27_1.bcr2016216535.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2012.08.006"},{"key":"2025082623334265000_2016.jul27_1.bcr2016216535.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2008.06.020"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2016-216535","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T06:33:58Z","timestamp":1756276438000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2016-216535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,27]]},"references-count":9,"alternative-id":["10.1136\/bcr-2016-216535"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2016-216535","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2016,7,27]]}}}